Standout Papers

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer 2011 2026 2016 2021 1.6k
  1. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer (2011)
    Robert A. Burger, Mark F. Brady et al. New England Journal of Medicine
  2. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer (2016)
    John K. Chan, Mark F. Brady et al. New England Journal of Medicine

Immediate Impact

3 by Nobel laureates 22 from Science/Nature 74 standout
Sub-graph 1 of 19

Citing Papers

CDK4 and CDK6 kinases: From basic science to cancer therapy
2022 StandoutScience
Design of biologically active binary protein 2D materials
2021 StandoutNatureNobel
2 intermediate papers

Works of Matthew Boente being referenced

Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
1995
Antibody‐induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c‐erbb‐2 (her‐2/neu) gene product p185
1993

Author Peers

Author Last Decade Papers Cites
Matthew Boente 2443 1467 791 896 53 3.7k
Sharon X. Liang 1928 1035 839 890 55 3.1k
Kenneth D. Swenerton 2309 2124 1223 1202 54 4.5k
Alexander Reuß 3301 1322 1239 636 86 4.2k
Debra A. Bell 1997 656 861 660 80 3.2k
P. Vasey 1452 1660 464 1252 97 3.7k
Margaret M. Steinhoff 1412 984 1135 865 77 3.8k
Alan N. Gordon 1915 1516 742 683 49 3.8k
Paul R. Kucera 2235 1055 847 557 31 3.3k
Carmen Tornos 1943 903 1878 935 90 4.3k
Amanda Hummer 910 1307 853 702 46 3.5k

All Works

Loading papers...

Rankless by CCL
2026